Natalie Holles, Third Harmonic Bio CEO

First of more? Third Har­mon­ic prices up­sized IPO to raise $185M

Third Har­mon­ic Bio pulled it off.

The At­las-found­ed biotech, which came out of stealth just ear­li­er this year with for­mer Au­dentes CEO Na­tal­ie Holles at the helm, has priced an IPO that will bring in $185.3 mil­lion be­fore tak­ing com­mis­sions, dis­counts and oth­er fees in­to ac­count.

Giv­en the chilly pub­lic mar­ket, it is per­haps un­usu­al that Third Har­mon­ic is mak­ing the jump to Nas­daq at all. No­tably, while it priced in the mid­dle of the pro­posed range — $17 per share — the com­pa­ny is boast­ing of an up­sized of­fer­ing. It end­ed up sell­ing more than 10 mil­lion shares rather than the 9 mil­lion orig­i­nal­ly planned.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.